Impact of Methods on the Measurement of mRNA Turnover by Wada, Takeo & Becskei, Attila
  
Int. J. Mol. Sci. 2017, 18, x; doi: FOR PEER REVIEW  www.mdpi.com/journal/ijms 
Review 
Impact of Methods on the Measurement of mRNA 
Turnover 
Takeo Wada and Attila Becskei * 
Biozentrum, University of Basel, Klingelbergstrasse 50/70, 4056 Basel, Switzerland; takeo.wada@unibas.ch 
* Correspondence: Attila.becskei@unibas.ch; Tel.: +41-61-207-22-22 
Received: 25 October 2017; Accepted: 8 December 2017; Published: date 
Abstract: The turnover of the RNA molecules is determined by the rates of transcription and RNA 
degradation. Several methods have been developed to study RNA turnover since the beginnings of 
molecular biology. Here we summarize the main methods to measure RNA half-life: transcription 
inhibition, gene control, and metabolic labelling. These methods were used to detect the cellular 
activity of the mRNAs degradation machinery, including the exo-ribonuclease Xrn1 and the 
exosome. On the other hand, the study of the differential stability of mature RNAs has been 
hampered by the fact that different methods have often yielded inconsistent results. Recent 
advances in the systematic comparison of different method variants in yeast have permitted the 
identification of the least invasive methodologies that reflect half-lives the most faithfully, which is 
expected to open the way for a consistent quantitative analysis of the determinants of mRNA 
stability. 
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1. Introduction 
mRNA turnover is determined by the rates of mRNA synthesis and degradation, which jointly 
adjust the level of gene expression [1–3]. 
The degradation of mRNAs in eukaryotes occurs largely in the cytoplasm and begins with the 
removal of the poly(A) tail. Subsequently, the degradation can proceed through two major pathways 
[4]. The mRNAs are processed either by the Xrn1p-mediated 5′ to 3′ degradation pathway after 
decapping or by the exosome (3′ to 5′) without decapping [5]. The molecular mechanisms have been 
already extensively reviewed [5]. 
Despite the central role of these enzymes in mRNA degradation, mutations in them often result 
in specific pathologies. For example, mutations in the RNA exosome cause neurodegenerative 
diseases [6]. Sequence variations in XRN1 have been frequently associated with susceptibility to 
bacterial diseases, such as Staphylococcus aureus infections, and have been also implicated in the 
altered defense against viruses [7,8]. 
mRNA half-lives have been measured since the inceptions of molecular biology [1–3]. Three 
main classes of methods have been available to study mRNA degradation rates: transcriptional 
inhibition, gene control, and metabolic in vivo labelling [9] (Figure 1). Transcriptional inhibition and 
in vivo labelling have been intensively used for the genome-wide measurement of mRNA half-lives 
for more than four decades. Despite the long history of mRNA half-life measurements, recent studies 
have revealed that different methods used to measure mRNA half-life often yield inconsistent data 
[10–12]. 
We will discuss the advantages and critical points of the employed methods and how they can 
be compared and optimized. We will also review the identification of the main components of the 
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degradation machinery from a historical-methodological perspective. Since these pathways were 
identified in the budding yeast Saccharomyces cerevisiae, we will focus on this eukaryotic model 
organism. 
 
Figure 1. Main classes of methods to study RNA stability. (a) Scheme of the molecular mechanism 
affected by the specific method procedures. In transcriptional inhibition, the RNA polymerase is 
inactivated; the expression of all genes is reduced. In the gene control method, a transcriptional 
activator dissociates from a specific promoter, shutting off the expression of the specific gene under 
the control of this promoter. For labelling of the RNAs, modified nucleotides are introduced into the 
cell (red dots), which are then incorporated into the RNA; (b) Time course of the experiments to 
determine RNA half-lives. Inhibition of transcription of the gene(s) is triggered at t = 0 in 
transcriptional inhibition and gene control methods. There are two subclasses of the in vivo labelling. 
In the approach to equilibrium method, a pulse of modified nucleotides is applied and the increase of 
the labelled mRNA is monitored. In the pulse–chase method, the RNA is first labeled (pulse period). 
During the chase period starting at t = 0, the labeled nucleotides are washed out and replaced with 
unlabeled nucleotides and the decline of the labelled RNA is monitored. 
2. Methods for the Measurement of RNA Degradation Rates 
2.1. In Vivo Metabolic Labelling 
Common to the variants of this method is that modified nucleotides are introduced into the cells 
to label the mRNA (Figure 2a, bottom panel). The RNA half-life can be deduced by quantifying the 
rate at which the labelled RNA increases or declines after the introduction or removal of the labelled 
nucleotides, respectively (Figure 2b, bottom panel). The labelling chemistry has changed over the five 
decades of the method’s employment. Initially, radioactively labelled nucleotides were used, 
especially [3H]-adenine and [32P]-phosphate [1,3]. Thereafter, their use has declined for several 
reasons. First, radioactivity may elicit cellular damage, including DNA double-strand breaks [13], 
and may trigger cellular signaling that alters transcription and RNA stability. Second, the invention 
of qPCR and high-throughput RNA detection technologies paved the way for the spread of labelling 
with non-radioactively modified nucleotides so that the labelled RNA can be separated from the total 
RNA to be quantified. If the RNA contains bromouracil (BrU), the separation is performed by 
immunoprecipitation. If the RNA incorporates 4-thiouracil, it can be biotinylated followed by binding 
to streptavidin beads [14,15]. The biotinylation-based separation has prevailed recently. 
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Figure 2. Impact of the speed of transcriptional inhibition on the measured mRNA half-lives. (a) Two 
different scenarios are shown for the inhibition of transcription. In the ideal case, the inhibition occurs 
instantaneously down to a baseline level (full line). In suboptimal cases, inhibition of transcription 
ensues with slow kinetics (dashed line); (b) The decay of RNA upon instantaneous (full lines) and 
slow (dashed lines) inhibition of transcription. The precursor mRNA (orange), containing the intron, 
can be used to monitor the inhibition kinetics since the precursor is converted rapidly to mature 
mRNA (purple) by splicing. The half-life of the mature mRNA (purple) will appear much longer with 
the slow inhibition kinetics and there is also a longer lag period before the mRNA level starts to 
decline. 
Interestingly, the uptake of 4-thiouracil and 4-thiouridine differs in mammalian and yeast cells. 
Uridine is a nucleoside containing uracil attached to a ribose. In yeast, only uracil and not uridine is 
imported into the cell efficiently. The intracellular uracil is then converted by the pyrimidine salvage 
pathway enzyme, the uracil phosphoribosyltransferase (Fur1) to uridine monophosphate, UMP [16]. 
In contrast, both compounds are transported into a mammalian cell but only uridine is incorporated 
into the RNA because the above salvage pathway is inactive [17]. For this reason, 4-thiouridine is 
mostly used in mammalian cells [14,15] and 4-thiouracil is used in yeast cells [18]. Initially, 4-
thiouridine was also used in yeast cells. To enable the uptake of 4-thiouridine (4sU), the human 
equilibriative nucleoside transporter (hENT1) was expressed in yeast cells [19]. Subsequently, 4-
thiouracil (4TU) was shown to be efficiently incorporated into yeast RNA [18], which permitted the 
use of a simpler chemical without the need to express exogenous genes in yeast cells. 
Each nucleobase derivative has different impact on cell physiology. Bromouridine is less toxic 
than 4-thiouridine in mammalian cells [20]. At elevated concentrations of 4-thiouridine (>50 µM), 
which are usually used for mRNA labeling experiments, the production and processing of rRNA is 
inhibited [21]. Thus, in vivo labeling can trigger a nucleolar stress response, which can interfere with 
the RNA stability measurements. 
The RNA half-lives can be determined by pulse–chase or by approach to equilibrium (Box 1). 
When the approach to equilibrium is followed, the increase of the labelled RNA upon addition of the 
modified nucleotides (pulse) is monitored. The rate of increase in the labelled RNA depends on the 
degradation rate [2], and not on the synthesis rate. In the pulse–chase method, a pulse of labelled 
nucleotide is added to the cells. In the subsequent chase period, the cells are washed with media 
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containing unlabeled nucleotides and the decline of the labelled RNA is monitored, as in the classical 
decay experiments.  
It is important to note that by varying the duration of the pulse, one can focus on different time-
scales of the RNA turnover [22]. Short pulses are particularly suitable to study fast processes, such as 
RNA splicing. 
2.2. Transcriptional Inhibitors 
When RNA expression is inhibited, all RNA species start to decay and by quantifying their 
change over time, their half-lives can be determined. In the earliest experiments, only cytoplasmic 
RNA expression was inhibited by blocking the export of RNAs into the cytoplasm; subsequently, 
transcription was inhibited to block the expression of RNAs completely. The inhibition of RNA 
expression can be achieved by small-molecule inhibitors or by creating temperature-sensitive alleles. 
The rna1 was one of the earliest examples of temperature-sensitive alleles that was used to determine 
RNA half-lives [23]. The RNA1 gene encodes a RanGAP, which generates the nucleocytoplasmic 
RanGTP gradient to drive the nucleocytoplasmic transport. Its inactivation causes a collapse of the 
gradient and transport [24]. By inhibiting RNA export, the level of cytoplasmic RNA and 
polyribosomes declines. Thus, the polyribosome fraction or the instantly synthesized proteins can be 
measured to infer the amount of cytoplasmic mRNAs [25]. Later, inhibition of the polymerase became 
the most widely used technique, which was facilitated by the isolation of the rpb1-1 allele. The 
standard name of RPB1 in budding yeast is RPO21 and it encodes the largest subunit of the RNA 
polymerase II [26].  
Box 1. Fitting of parameters to determine RNA half-lives. 
Just like radioactive decay, the decay of mRNA molecules is typically described by an 
exponential function.  
( ) 0 ktR t R e−=  (1) 
R0 and R(t) denote the RNA level at the initial and subsequent time points, respectively, and the 
decay rate constant is k = Ln [2]/t1/2. 
When the initial level of the RNA is zero then the time to reach the steady-state (equilibrium) is 
determined also by the decay rate, and not—as often incorrectly assumed—by the synthesis rate, p. 
( ) ( ) 1 ktpR t ek
−= −  (2) 
The above equation and the half-life in it can be fitted to the time series of (labelled) RNA 
levels upon induction of gene expression or upon addition of modified nucleotides. The time to 
reach the half-saturation corresponds exactly to the half-life [1–3]. 
Equation (1) is used to fit half-lives in transcriptional inhibition and gene control experiments, 
while both Equations (1) and (2) are used for in vivo labelling experiments. 
Transcriptional inhibition can be used for genome-wide measurements of RNA decay, which 
contributed to the popularity of this approach, even though potential disadvantages have been 
known. The stepwise increase of temperature required for the thermal inactivation of the polymerase 
and the rapid loss of labile factors upon transcriptional inhibition may have pleiotropic effects on cell 
physiology. A study using metabolic labelling has revealed that the rpb1-1 allele alters the mRNA 
stability even at permissive temperature [11].  
Chemicals, such as 1,10-phenanthroline and thiolutin, have been also used to inhibit the RNA 
polymerases. They, too, have their disadvantages. 1,10-phenanthroline, a heterocyclic compound, 
inhibits a large number of enzymes in addition to the RNA polymerase, especially zinc 
metalloproteases [27]. The action of thiolutin, a dithiolopyrrolon antibiotic isolated from the 
Streptomycetes luteosporeus, has been thought to be a more specific inhibitor of transcription. 
Interestingly, recent studies have unveiled that thiolutin can also chelate Zn, and inhibit 
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metalloproteases, including a deubiquitinating enzyme of the proteasome [28,29]. Furthermore, the 
mRNA half-life measured with thiolutin strongly depends on the applied concentrations [30].  
To inhibit transcription in mammalian cells, mostly actinomycin D has been used, which is an 
antibiotic isolated from the Streptomyces parvulus. It inhibits the elongating RNA polymerase (RNAP). 
Elongation blockage induces the proteasomal degradation of RPB1, mediated by the p53 tumor 
suppressor [31]. RPB1 is the subunit 1 of the RNA polymerase II. While actinomycin D inhibits all 
isoforms of the RNA polymerases, α-amanitin is highly selective for RNAP II and RNAP III but its 
action is slow. New compounds have also been identified that are fast, selective and able to 
completely arrest transcription by triggering rapid degradation of RNAP II [32], which may reduce 
the side-effects of transcriptional inhibition to study mRNA turnover. 
2.3. Gene Control 
Gene control and transcriptional inhibition are related methods since gene expression is shut off, 
and the mRNA level starts to decline. The two methods differ with respect to the scale of inhibition. 
With transcriptional inhibition, the expression of all genes is inhibited. On the other hand, the 
expression of a single gene is shut off in the gene control method, in which a gene is placed under the 
control of a regulatable promoter, such as the GAL or the TET promoter [9]. Despite the lesser 
probability of having side effect, the gene specific control has been rarely used because each 
experiment only yields the half-life of a single mRNA.  
The advantage of the TET system is that it is of bacterial origin and thus orthogonal to the 
endogenous processes in eukaryotes. Doxycycline, which is often used to control the TET system, has 
no or minimal effect on the expression of the S. cerevisiae genome [33]. Doxycycline dissociates the 
tetracycline transactivator (tTA) from the promoter. It is important not to use a too strong promoter 
to express the tTA because high expression of the activator may cause cellular growth defects and 
major alterations in gene expression [34]. A moderately strong promoter (e.g., MYO2) generates 
sufficient expression of tTA without causing growth defects [35].  
Alternatively, a TetR-repressor fusion protein can be recruited to tet operators inserted into 
promoters to shut off gene expression, using classical general repressors such as Ssn6p or Sum1p [12]. 
This strategy has the advantage that it is even less invasive since the original promoter sequence is 
retained upon the insertion. On the other hand, not all repressors have a fast action and not all 
promoters can be efficiently repressed. 
The TET system can be used also in mammalian cells. Pre-exposure of cells to low concentration 
of doxycycline was shown to improve the decay kinetics, possibly because the reduced expression of 
some genes eliminated the side effects [36]. Thus, the system may require prior optimization. Since 
most mammalian genes are very long and contain multiple introns, the cloning of mammalian genes 
into plasmids is limited technically, which can be a serious impediment to implement the gene control 
method. The cloning of the full length gene is desirable as it has been known that mRNA processing, 
including splicing, is strongly dependent on the chromatin state [37].  
The GAL promoters in yeast are active in the presence of galactose and are repressed by glucose. 
When cells are grown in glycerol or in the neutral sugar raffinose, the GAL promoters are inactive. 
The expression of most genes in the inactive state is similar to or slightly higher than the expression 
in the repressed state [38]. To shut off GAL driven transcription in cells grown in galactose, glucose 
is added at high concentrations [3]. It is important to note that glucose triggers a signal that can 
transiently increase the decay rate of some mRNAs [38]. Therefore, the decay rate may not reflect the 
steady-state turnover for these mRNAs. To avoid the transient signaling due to the shift from 
galactose to glucose, galactose can be washed out and replaced by the neutral sugar, raffinose [12], 
which results in half-lives similar to those obtained with the TET system [38]. In this case, it is 
recommended to use lower galactose concentration for induction to expedite its transport out of the 
cell [39]. In fact, the high galactose concentrations (2%), used in most studies, are not needed because 
the GAL genes can be already induced at as low concentration as 0.05% [38].  
Int. J. Mol. Sci. 2017, 18, x FOR PEER REVIEW  6 of 13 
 
2.4. Additional Methods 
The above three major classes of methods yield RNA half-lives directly. There are also methods 
that can be used to estimate half-lives indirectly. For example, the half-life can be calculated when 
the RNA synthesis rate constant and the mRNA concentration are known. The mRNA synthesis rates 
can be measured by genomic run-on experiments by stopping transcription and by resuming it in the 
presence of labelled nucleotides so that the nascent transcripts are extended [40].  
In principle, it is also possible to deduce mRNA half-lives from steady-state expression of RNAs 
measured in single cells, provided the regulating transcription factor undergoes large-amplitude 
nucleocytoplasmic oscillations. [41]. Upon export of a transcription factor to the cytoplasm, the 
decline of mRNA can be observed in single cells and the RNA half-life can be in principle estimated. 
Such singe cell observations require the insertion of stem-loops into the RNA. Since stem-loops can 
affect RNA processing [42], the mRNA stability has to be assessed before and after insertion of stem-
loops.  
3. Comparison of the Average mRNA Half-Lives 
Ever since RNA stability was studied, it has been assumed that each method can affect the 
measured half-lives. Consequently, mRNA half-lives obtained by different methods have been 
repeatedly compared. Two measures have been used for the comparison: the average half-life and 
the correlation. 
There are two common measures of the average: the mean and the median. The mean half-life 
has been mostly reported in the earlier studies, while the median is mostly reported in the later ones. 
The median is typically larger than the mean because the distribution of the half-lives is often skewed 
to longer half-lives. The overwhelming majority of the studies yielded average mRNA half-lives 
between 10 and 25 min, using in vivo labelling or transcriptional inhibition [12,25,43]. A recent study 
reported a median half-life of around 2 min, representing a substantial deviation from the above 
range [12]. Such short-lives have been typically found only in prokaryotes [44].  
What could be the reason for the considerable differences among the measured half-lives? In an 
ideal case, the inhibition transcription or the incorporation of labelled nucleotides occurs 
instantaneously after starting the experiment. In practice, these processes occur after a lag period or 
with a slower than expected kinetics. Using dual labelling experiments, the lag time due to the 
incorporation of nucleotides has been estimated to be around 5 min in yeast [1].  
Inhibition of the polymerase can also introduce a lag that is dependent on the gene length 
because initiation and elongation is inhibited with different efficiencies [44].  
A simple exponential model of decay assumes that the inhibition of transcription is 
instantaneous or occurs very rapidly (Box 1). This may or may not be true and should be verified. It 
is not easy to monitor directly how rapidly transcription declines. The level of the un-spliced 
precursor mRNA provides a good proxy for the precipitously changing transcription rate because 
splicing of the precursor mRNA is typically faster than the RNA decay (Figure 2). To monitor 
transcription, mRNAs have to be selected that undergo a fast, efficient splicing, which can be inferred 
from the ratio of the mature to the precursor RNA. The larger the mature-to-precursor ratio, the faster 
the splicing. If the ratio is 100 then the precursor amount is expected to decline 100 times faster via 
splicing than the mature mRNA via decay. At lower splicing rates, the formula for this ratio has a 
correction term that takes into account the escape of the unspliced precursor mRNA from the nucleus 
to the cytoplasm [45,46].  
Despite the importance of this control experiment, relatively few studies have reported the half-
time of the precursor RNA [47,48]. The reported values range between 0.5 and 1 min, which constitute 
the lower limit of the half-lives that can be reliably detected. If the experimental set-up is not optimal 
and the precursor declines slowly, the experimental conditions can be modified to accelerate the 
transcriptional inhibition. For example, thermal inactivation of the polymerase at 39 °C instead of  
37 °C accelerates the inhibition [48]. 
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4. Correlation as a Measure of Method Reliability 
The similarity of the average half-lives in the majority of the studies may have led to the belief 
that the methods are consistent. However, more recent studies focused on the correlation between 
the mRNA half-lives, which turned out to be surprisingly low [10–12]. This means that different 
methods classify different mRNAs as stable or unstable. 
There are two types of correlation coefficients: the Pearson’s product-moment and Spearman’s 
rank correlation coefficients. When the distribution of the half-lives is not Gaussian then the 
Spearman’s rank correlation should be used. The rank correlation coefficient is less sensitive to 
outliers. The higher the correlation between two methods, the more likely that the same mRNAs will 
be classified as stable or unstable. 
There is no uniform way to delimit the lowest acceptable value of correlation. Generally, values 
between 0.3 and 0.5, and between 0.5 and 0.7 reflect low and moderate correlations, respectively. 
Values above 0.7 are considered high. It is instructive to consider a field in molecular biology where 
correlation is used to assess the robustness of predictions. For example, correlations have been used 
to predict biological age of an individual from unknown tissue samples based on epigenetic markers. 
Methylation of CG dinucleotides (CpG), a classical epigenetic mark, increases with age. Accordingly, 
the CpG methylation of appropriately selected promoters can be used to predict age based on 
biological samples. The correlation between the CpG methylation percentage and age can be then 
used for linear regression to predict age from biological samples [49,50]. Different gene selections 
yield different values for the correlations and thus have different predictive power. Some selections 
yield correlation coefficients of 0.7, while others surpass even 0.9, which is equivalent to a prediction 
error of ±3 years in the range above 20 years of age [49,50]. Thus, as rule of thumb, a correlation 
coefficient of 0.7 or more indicates that the respective methods can be used to determine RNA half-
lives with a relatively high precision. 
5. Internal Consistency and Inter-Method Reliability: From Simplicity to Perplexity 
In one of the first comparative studies, the half-lives of 11 mRNAs were measured using the 
temperature sensitive polymerase (rpb1-1) and in vivo labelling with [32P]-phosphate [3]. The two 
methods yielded similar decay rate constants for around half of the examined RNA species but four 
mRNAs displayed marked discrepancies. By analyzing the poly(A)+ mRNA, the authors suggested 
that the kinetics of deadenylation may account for the discrepancy.  
This study was followed by the first genome-wide comparison [10], which examined the 
consistency of the rpb1-1 method. The internal consistency of a specific method can be assessed by 
calculating the correlation between two studies using the same method variant. The authors found 
that the correlation was nearly three times higher for highly expressed genes (R = 0.48 at the 90th 
percentile) than for weakly expressed genes (R = 0.15 at the 10th percentile), which suggests that the 
weak signal intensity may introduce considerable measurement error. 
A more recent study assessed both internal consistency and inter-method reliability. Two 
variants of the metabolic labelling employing different pulsing protocols yielded uncorrelated half-
lives [11]. The comparison of five different studies using the same variant of the same method (rpb1-
1 allele of the polymerase) indicated a low reproducibility of the method, with the Spearman’s rank 
correlation coefficient between five different studies ranging between 0.28 and 0.77 [11]. Furthermore, 
there was no correlation between the transcriptional inhibition and metabolic labelling studies.  
To explain the discrepancy between the transcriptional inhibition and in vivo labelling, the study 
using a variant of the metabolic labelling, the cDTA, found that the rpb1-1 allele increases mRNA 
stability even at permissive temperature [51]. Similar stabilization was found with gene control 
measurements when decay was measured in cells with mutant polymerases with reduced elongation 
rates [52]. Thus, there is a global interdependence between the transcription and degradation 
machinery [12,53]. This includes both direct and indirect effects. Transcriptional inhibition reduces 
Xrn1p levels directly, resulting in diminished RNA decay rates. An indirect effect on RNA synthesis 
rates has been also suggested, mediated by a specific transcriptional repressor [51].  
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Since two studies using metabolic labelling did not correlate with each other and with the 
inhibition studies [11], it was difficult to justify why metabolic labelling should supersede the 
transcriptional inhibition methods. This conundrum was resolved in part by a recent study using a 
multiplexed version of the gene control method using the TET system, which yielded half-lives with 
a high correlation to one version of the metabolic labelling, the cDTA, with a rank correlation 
coefficient of 0.77 [12]. This high correlation can be particularly appreciated from the perspective that 
the two studies are methodologically independent, since they introduce different perturbations into 
the cells. Despite the large positive correlation between the gene control and the cDTA variant of 
metabolic labelling, there is a significant difference in the median half-lives. The five-times-longer 
half-life in the cDTA study may be explained by the slow incorporation of the labelled nucleotides 
into the RNA. The slow incorporation may in turn caused by the slow cellular uptake of uracil, which 
is controlled by a complex regulatory circuit. The uracil inhibits its own import by the uracil permease 
Fur4p. The half-lives of both the RNA and protein products of the FUR4 gene are reduced upon 
exposure to uracil [54]. Thus, the high concentration pulse of labelled nucleotides may slow down 
the uptake and incorporation of labelled uracil.  
It is somewhat surprising that there is no correlation between two variants of the metabolic 
labelling [11]. What may explain this discrepancy? This inconsistency cannot be explained 
unequivocally because the applied protocols differ at multiple points. The study by Munchel et al. 
employs the pulse–chase approach, the RNA is labelled with low nucleotide concentration (0.2 mM 
TU for 3 h in a log-phase culture) and the RNA is quantified by high-throughput sequencing. On the 
other hand, cDTA uses the approach to equilibrium method upon exposing the cells to high 
nucleotide concentrations (5 mM TU for 6 min in a log-phase culture), and the RNA was quantified 
by microarray. A comparison of multiple in vivo labeling studies to an independent method, the 
multiplexed gene control, can help to narrow down the reasons for the discrepancy. The multiplexed 
gene control method correlates more with the cDTA than with the RATE-seq [12]; and RATE-seq 
employs RNA-seq for RNA quantification [55]. Thus, microarray may have delivered more precise 
measurements than RNA-seq. This conclusion is strengthened by knowing that the RATE-seq was 
expected to yield more robust half-life estimates because multiple time points were measured in 
RATE-seq, whereas only a single time point was measured in the cDTA study. 
The methods applied to measure the half-life can perturb the cell or RNA turnover, and each 
method can have a differential effect on the stability of individual mRNAs. Therefore, it is possible 
that a sequence motif identified with a particular method reflects the interaction of the perturbation 
with the cell rather than the original half-life. Thus, using two independent methods or cross-
validated methods can ensure that a motif identified reflects the parameter to be measured. This is 
particularly important because RNA decay may be determined not only by simple sequence motifs 
but also by RNA secondary structure [56] and by the translation efficiency of the mRNA [57].  
6. Comparison of Half-Lives in Mammalian Cells 
A systematic comparison of mRNA stabilities in mammalian cells is hampered by the large 
variety of cell lines and differentiation states. A study using global transcriptional inhibition with 
actinomycin D reported a median mRNA half-life of 10 h [58]. Two studies used 4-thiouridine (4sU) 
labeling in the same cell line (NIH3T3) [14,59]; the correlation between these two data sets was 
moderate (R = 0.64), having median half-lives of 7.6 and 4.6 h. A metabolic labelling study with 4sU 
labelling reported considerably shorter mRNA half-lives in dendritic cells, in the range between 10 
and 70 min [47]. Thus, cross-validation of methods will be important also for mammalian cells.  
7. Identification of the RNA Degradation Machinery: Xrn1, Exosome and the Nonsense Mediated 
Decay 
Next, we will review how the major components of the mRNA degradation machinery were 
discovered, from a historical-methodological perspective. All the major components, the Xrn1 and 
exosome, and the major surveillance pathway (nonsense mediated decay) were identified in the yeast 
Saccharomyces cerevisiae. 
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7.1. Xrn1: 5′-to-3′ Degradation 
The Xrn1 protein was identified biochemically as a 5′-to-3′ ribonuclease activity on uncapped 
mRNA. Capped mRNAs were shown to be quite resistant to degradation by the purified Xrn1p [60]. 
The 5′ cap, found on the 5′ end of the messenger RNAs, consists of a methylated guanine nucleotide 
connected to the mRNA via an unusual triphosphate linkage. Upon identifying the gene encoding 
the Xrn1p, it was shown to be a non-essential gene but its deletion causes a marked growth defect 
[61]. To link the in vivo activity of Xrn1 to mRNA decay, a transcriptional inhibition study using 
thiolutin and phenanthroline revealed that Xrn1 affects particularly the stability of mRNAs with short 
lives [62]. Subsequently, a gene control experiment with the GAL promoter confirmed the 
involvement of XRN1 in the regulation of the half-life of the unstable MFA2 and stable PGK1 mRNAs 
[63]. The methods relying on rpb1-1 was used to show that the glucose-dependent stability of an 
mRNA is Xrn1-dependent [64]. Xrn1 also controls the levels of sense-antisense mRNA pairs, which 
can arise as a result of convergent gene expression [65].  
Little is known about the regulation of Xrn1; subcellular sequestration of Xrn1 may play an 
important role. The protein is diffusely distributed in the cells in exponentially growing cultures but 
becomes localized to the cytoplasmic P-bodies at the diauxic shift. Subsequently, at the post-diauxic 
stage, Xrn1 is localized to the plasma membrane, which prevents mRNA degradation, as shown by 
the reduced decay of the MFα2 mRNA using a TET-based gene control method [66].  
It has been shown that the Xrn1p undergoes rapid evolution, as evidenced by the large sequence 
divergence of XRN1 among related yeast species [67]. This may in part explain the multiple functions 
of Xrn1p. Xrn1p is primarily an exoribonuclease but has other functions in the cell, which are often 
denoted by different aliases. Of practical importance is the KEM1 alias, which refers to Kar-enhancing 
mutations: haploid cells with xrn1 deletion have a very low mating efficiency due to a defective 
karyogamy [68]. The defective fusion of two nuclei makes the construction of xrn1 null diploid cells 
difficult. 
7.2. Exosome: 3′-to-5′ Degradation 
The main component of the second pathway of mRNA decay is the exosome, which is a multi-
protein complex with a 3′-to-5′ ribonuclease activity [69]. The exosome has also a nuclear function. It 
was isolated and identified by mass-spectrometry [70]. It is more difficult to study the effect of the 
exosome because the deletion of its components is lethal. It is however possible to delete the SKI 
genes; the Ski proteins bridge the exosome and the RNA. The in vivo activity of the exosome was 
studied by combining the inactivation of the decapping protein Dcp1 with the deletion of SKI8 [71]. 
Individual mutation of each of the genes had little effect on the decay rates of the GAL and MFA2 
RNAs as studied by the gene control method, using the GAL promoter. However, when both of these 
proteins were inactivated, the half-life of the mRNAs lengthened around 6–7 times [71].  
7.3. Nonsense Mediated Decay (NMD) 
So far, few stability sequence motifs have been identified with dominant effect on stability when 
transferred to other mRNAs. A simple sequence that consistently changes the half-life of the mRNAs 
is the premature stop codon [72–74]. Just like the main components of the eukaryotic mRNA 
degradation machinery, this phenomenon was discovered in budding yeast. Using radioactive 
labelling, it was shown that premature stop codons—in a position dependent manner—alter the 
stability of mRNAs without affecting the transcription rate [73]. This phenomenon, known as 
nonsense mediated decay (NMD), was shown to be mediated by the Upf1p, using transcriptional 
inhibition with the rpb1-1 mutant [72]. The closer the stop codon to the 5′-end of the stable PGK1 
mRNAs was, the more strongly the mRNA got destabilized [74]. NMD was also confirmed with gene 
control experiments [45]. There are two main sources of mRNAs subject to NMD. First, premature 
stop codons can arise by mutations during transcription, a phenomenon termed transcriptional 
infidelity [75]. Second, a fraction of the unspliced RNA escapes from the nucleus into the cytoplasm 
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and the retained introns contain a large number of premature stop codons [45,46]. NMD can also 
affect mRNAs that lack premature stop codons but are prone to out-of-frame translation [76]. 
8. Conclusions 
In vivo labelling and inhibition of RNA expression have been used for at least four decades to 
measure RNA half-lives. Surprisingly, only recent studies unveiled that the two methods yield half-
lives with no or minimal correlation. A more recent study showed that there is a high correlation 
between specific variants of the in vivo metabolic labelling and gene control methods. The 
consistency between two independent methods indicates high inter-method reliability. Thus, some 
variants of the genetic control and metabolic labelling may reflect the half-lives the most faithfully. 
However, there is no guarantee that using a method class, let it be metabolic labelling or gene control, 
will deliver the half-lives faithfully. If the conditions are not optimal, such as the concentration of the 
labelled nucleotide or the expression level of the activator that controls the gene, the measured half-
lives and RNA synthesis rates may be inconsistent.  
The most robust methods are expected to have played a major role in the identification of the 
molecular machinery of mRNA degradation. In most cases, in vitro biochemical studies were first 
undertaken. Subsequently, the in vivo activities of the identified components were confirmed by most 
of the major methods. Thus, all methods capture RNA decay, at least qualitatively. However, current 
evidence indicates that specific variants of the gene control and metabolic labelling methods can be 
used with high reliability to quantify the differential stability of mature mRNAs. We expect that the 
confirmation of mRNA stabilities by two different methodologies and further developments in the 
analysis of inter-method reliability will help to identify mRNA stability determinants. 
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